PAREXEL APPOINTS BIOMEDICAL AND INFORMATION SCIENCES EXPERT, DR. BARBARA TARDIFF, TO VICE PRESIDENT OF DATA SCIENCES
BOSTON, MA, May 22, 2007 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, has appointed Dr. Barbara Tardiff, M.D., M.S., M. Phil. to the newly created position of Corporate Vice President of Data Sciences. Drawing from nearly 25 years of experience in medicine, information management, and clinical research, Dr. Tardiff will lead the expansion of PAREXEL’s data services including data management, biostatistics and related applications of information technology.
Dr. Tardiff joins the organization after two and a half years with Merck & Co. where she was Executive Director, Research Information Services. She previously served as Vice President of Informatics, Data Management and Biostatistics at Regeneron Pharmaceuticals.
“PAREXEL’s clients are anticipated to benefit significantly from Dr. Tardiff’s depth of experience in applying information technology to clinical development,” said Mark A. Goldberg, M.D., President, Clinical Research Services and Perceptive Informatics at PAREXEL. “With her leadership and guidance, PAREXEL will be able to better leverage it’s clinical and technology expertise.”
“It is a pleasure to be working with some of the industry’s most notable physicians, researchers and technologists,” said Dr. Tardiff. “PAREXEL is known for its technology and clinical expertise. I am excited to have the opportunity to bring these two strengths together and apply them to the challenges and opportunities that our customers face, such as adaptive clinical trials.”
Dr. Tardiff is certified by the American Board of Pediatrics and the American Board of Anesthesiology and completed a clinical research fellowship at the Duke Clinical Research Institute. She currently holds several prestigious consultancy appointments including Assistant Consulting Professor, Duke University School of Medicine and is an occasional lecturer at Fuqua School of Business, Duke University. She is a member of the Drug Information Association’s (DIA) Information Technology Track Program Committee and has been an active participant in various Health Information Technology forums. Dr. Tardiff is also active in industry standards initiatives such as CDISC and Health Level Seven (HL7), and served as co-chair of the HL7 Regulated Clinical Information Management Technical Committee for five years. Her research has been featured in numerous publications including the Journal of the American College of Cardiology and the American Heart Journal.
Dr. Tardiff holds an MD from Yale University, an MBA from Duke University, Fuqua School of Business, an MS, M. Phil from Yale University, and a BS from Oregon State University. She is based at PAREXEL’s worldwide headquarters in Waltham, Massachusetts.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 55 locations throughout 43 countries around the world, and has over 6,315 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2007 as filed with the SEC on May 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.